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Narita 104 virus is a human pathogen belonging to the norovirus (family Caliciviridae) genogroup II. Noroviruses cause epidemic
gastroenteritis worldwide. To explore the potential of developing a plant-based vaccine, a plant optimized gene encoding Narita 104
virus capsid protein (NaVCP) was expressed transiently inNicotiana benthamiana using a tobacco mosaic virus expression system.
NaVCP accumulated up to approximately 0.3mg/g fresh weight of leaf at 4 days postinfection. Initiation of hypersensitive response-
like symptoms followed by tissue necrosis necessitated a brief infection time and was a significant factor limiting expression.
Transmission electron microscopy of plant-derived NaVCP confirmed the presence of fully assembled virus-like particles (VLPs).
In this study, an optimized method to express and partially purify NaVCP is described. Further, partially purified NaVCP was used
to immunize mice by intranasal delivery and generated significant mucosal and serum antibody responses. Thus, plant-derived
Narita 104 VLPs have potential for use as a candidate subunit vaccine or as a component of a multivalent subunit vaccine, along
with other genotype-specific plant-derived VLPs.
1. Introduction
Noroviruses (NoVs), which belong to the family Caliciviri-
dae, are the leading causes of acute viral gastroenteritis in
humans worldwide. NoVs are approximately 38 nm icosa-
hedral viruses and contain a positive-sense, single-stranded,
nonenveloped RNA genome of ∼7.5 kb [1]. The open reading
frame (ORF) 1 encodes nonstructural proteins required for
viral replication. ORF2 codes for the capsid protein and the
ORF3 encodes a small basic protein that is a minor structural
protein included in the virion [2–4].Themajor capsid protein
can diverge by as much as 60% between genogroups and 20–
30% between genotypes within a genogroup. Human NoVs
are classified into two distinct genogroups (GI and GII) [5]
which are further subdivided into more than 25 different
genotypes. The majority of norovirus outbreaks currently
are caused by the GII.4 genotypes, which cause significant
morbidity and mortality [6]. Several viruses in this category
have emerged since 1990s worldwide [7–15].Thus, we studied
the development of a plant-based vaccine against Narita 104
virus (NaV) (NCBI database, accession number AB078336),
a GII.4 strain of norovirus [16].
Heterologous expression of recombinant Norwalk virus
capsid protein (NVCP) in insect and plant systems showed
that the capsid protein can self-assemble into virus-like
particles (VLP) that are morphologically and antigenically
similar to native NV particles [17–19]. Recombinant Norwalk
virus VLP (rNV VLP) elicited VLP-specific systemic (serum
IgG) and mucosal (vaginal and fecal IgA) antibodies in mice
when administered orally in presence and in the absence
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of an adjuvant [18, 20, 21]. The plant-based expression of
native NaV capsid protein was poor due to incorrect mRNA
processing, but a plant optimized gene enhanced expression
[22]. Also, new approaches to achieving high levels of protein
using rapid virus-vectored transient expression have been
developed, including the tobaccomosaic virus (TMV) system
(ICON system) [23–25].
A commercial vaccine to prevent norovirus infection
is not currently available. For the successful design of a
norovirus vaccine, variability of capsid protein in different
genotypes must be taken into account [16, 17, 26–28]. Plants
are an economical and safe platform for vaccine development
due to ease of scalability and lack of mammalian pathogens
[29, 30]. The ICON system allows for rapid and scalable
production of various antigens.Thus, within a short period of
time multiple vaccine candidates can be expressed and tested
for their efficacy [21, 31–34].
In this study, we performed plant-based expression and
partial purification of Narita VLP (NaVLP) and further
evaluated these VLPs as a candidate vaccine by testing
the immunogenicity and induction of GII.4-specific VLP
antibody in mice.
2. Materials and Methods
2.1. Construction of Plant Expression Vector. A plant-
optimized sNaVCP gene (Genbank accession number
GQ389627) from pCRblunt-sNaVCP [22] was introduced
into pICH10990 (ICON Genetics, Halle, Germany) to obtain
pICHsNaV. The coding sequence in pCRblunt-sNaVCP
was end-tailored to create an EcoRI site at the 5󸀠 end using
a high-fidelity PCR kit (Roche) with primers sNaCP-eco
(5󸀠-GACGAATTCAACAATGAAGATGGCTTCTAATG)
and M13RHT (5󸀠-GGAAACAGCTATGACCATG). The
resulting PCR product was digested with EcoRI-SacI
and the fragment was ligated into pICH10990 digested
likewise to yield pICHsNaV (3󸀠 module). The plasmid was
sequenced to assure fidelity and mobilized into Agrobacteri-
um tumefaciens GV3101. The two modules containing the
integrase (pICH14011) and the 5󸀠 module (pICH15879) that
mediates cytosolic accumulation were coinfiltrated along
with the 3󸀠 module [24]. For expression of NVCP and GFP,
the 3󸀠 module vectors pICH-sNVCP and pICH-GFP [21]
were used.
2.2. AgrobacteriumDeliveryUsingVacuum Infiltration. Equal
volumes of overnight-grown Agrobacterium cultures (3󸀠
module, integrase, and 5󸀠 module), OD
600
≈ 1.8, were
mixed and sedimented at 6,000×g for 3min. The pellet
was resuspended in 15mL of a solution containing 10mM
MES (pH 5.5) and 10mM MgSO
4
in order to obtain the
final combined OD600 of ∼0.1. Four-week-old greenhouse
grown N. benthamiana plants were submerged upside down
in polystyrene cylindrical flasks (6 cm height, 7 cm diameter)
containing 2.5 L of the bacterial suspension and transferred to
a desiccator. Vacuum (23 in.Hg)was applied for 2min using a
pump (Welch model number 2546B-01) and gently released.
Gentle shaking of the desiccator was performed during
vacuum application to remove air bubbles. After confirming
the success of the infiltration by visual inspection (infiltrated
areas of the leaf become translucent when observed against
a source of light), plants were placed in the growth room to
recover.
2.3. RNA Extraction and Hybridization. Total RNA was
extracted from leaves of tobacco (Trizol reagent, Invitrogen)
and residual DNA removed by DNA-free system (Ambion).
RNA was fractionated on formaldehyde agarose gels and
blotted to nylonmembranes as described [35].Themembrane
was hybridized with digoxigenin-labeled probe synthesized
by PCR using primers 3󸀠UTR-F (GAGCTCCCGGGGATC-
CTCTA) and 3󸀠UTR-R (TTAGGGAGGATTCGAACCTCT-
CAC) and pICHsNaV as template, as described in the product
literature (Roche).
2.4. Protein Extraction. Four days postinfiltration (DPI), N.
benthamiana leaves were harvested, weighed, flash-frozen in
liquid N
2
, and stored at −80∘C. For total protein extraction,
frozen leaves were homogenized by blending in extraction
buffer [25mM sodium phosphate (pH 6.6), 100mM NaCl,
1mM EDTA, 50mM sodium ascorbate, and 10 𝜇g/mL leu-
peptin] at the ratio of 10mL per gram of fresh weight of leaf.
Homogenates were then immediately filtered through Mir-
acloth (Calbiochem) and centrifuged at 11,300 g for 20min
at 4∘C. The supernatant was passed through 0.22𝜇m filter
(Millipore) and kept at 4∘Cbefore concentrating using stirred
cell (Amicon, model number 8200, Millipore) with 300 kDa
cut-off membrane (Ultracel PL30000; Millipore) followed
by further filtration through a 30 kDa cut-off membrane
(Biomax PB 300,000; Millipore). The retained concentrated
extract was used for further analysis.
2.5. SDS-PAGE andWestern Blot. Samples were denatured by
boiling in SDS-PAGE buffer and resolved using 4–20% gra-
dient polyacrylamide gels and followed by either Coomassie
brilliant blue G-250 staining with PageBlue protein staining
solution (Fermentas) or electrophoretically transferred to
Hybond P membrane (Amersham Pharmacia) for Western
blot. Membranes were probed with rabbit polyclonal anti-
NaV antibody conjugated to HRP diluted 1 : 5000. The mem-
branes were developed by chemiluminescence using the ECL
plus detection reagent (Amersham Pharmacia).
2.6. NaVCP ELISA and Bradford. Plant extracts were ana-
lyzed by NaVCP sandwich ELISA. Recombinant NaVCP
derived from insect cells using baculovirus system (i-NaV,
gift of N. Takeda) served as reference standard. Briefly,
rabbit anti-NaV 104 serum was diluted to 1 : 10,000 in 0.01M
phosphate-buffered saline (PBS; 50 𝜇L per well) and coated
on the 96-well plate using carbonate high binding buffer for
4 h at 23∘C. The plates were then blocked with 5% nonfat
dry milk in PBS with 0.05% Tween 20 (DM/PBST) for 1 h at
23∘C. After washing the wells once with 1X PBST, samples
(50 𝜇L per well) diluted in 1%DM/1X PBST were added
and incubated for 1 h at 37∘C. The wells were washed three
times and incubated for 2 h at 37∘C with rabbit anti-NaV104
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IgG-horseradish peroxidase conjugate, diluted 1 : 20,000 in
1%DM/PBST. The plate was developed with TMB detection
kit (Amersham Biosciences) for 8–10min at 23∘C and the
reaction was ended by adding 1M H
3
PO
4
. Absorbance was
read at 450 nm. For standard curve, i-NaVwas diluted serially
twofold in 1%DM/1X PBST from concentrations starting at
12.5 ng/mL and processed as above. The leaf supernatants
were tested for total soluble protein (TSP) by the Coomassie
blue dye-binding assay [36] using reagent (Bio-Rad) with
BSA as a standard.
2.7. Sucrose Gradient Sedimentation. The sucrose gradient
was performed as described [21] with modifications. Briefly,
gradients were generated using 60, 50, 40, 30, 20, and 10%
sucrose prepared in 0.01M PBS and incubated for at least
2 h at 4∘C to allow for formation of continuous gradient.
The sample (either crude leaf extract or previously purified
NaVLP)was layered on the top of the gradient, and tubeswere
centrifuged at 151,000 g for 2.5 h at 4∘C. Fifteen fractions were
generated and analyzed by ELISA.
2.8. Electron Microscopy. Pooled sucrose gradient fractions
were analyzed by antibody immobilization negative stain-
ing and examination by transmission electron microscopy
(TEM). Formvar coated Ni grids were coated with rabbit
polyclonal anti-NaV antibody (1 : 10 dilution) for 10min at
23∘C. Samples were applied to antibody-coated grids for
10min. After washing, grids were stained using 2% uranyl
acetate for 1min and examined with a Philips CM-12 TEM.
2.9. Anion Exchange Chromatography. Anion exchange chro-
matography was performed as described [37] with slight
modifications. The concentrated sample was applied to
packed columns (1.5 × 12 cm, Bio-Rad) containing DEAE
Sepharose Fast flow (GEHealthcare) that was preequilibrated
with buffer (25mM sodium phosphate, 100mM NaCl, pH
5.8). The flow-through containing NaVCP products were
collected separately after washing five times with the same
buffer. Final elution was done with high salt buffer (2MNaCl
in 25mM sodium phosphate buffer, pH 5.8) and collected
separately. The flow-through fractions containing most of
the NaVCP products were pooled and then concentrated
again using 30 kDa cut-off membrane (Centriprep YM-30,
Millipore) and analyzed by SDS-PAGE gel and ELISA. The
partially purified sample was used for immunization studies.
2.10. NaVCP Immunization inMice. All animals were housed
in American Association for Laboratory Animal Care,
approved quarters, and were provided unlimited access to
food and water. All procedures were approved by the ASU
IACUC and performed in accordance with the Animal
Welfare Act. Female 5-week-old BALB/cmice (Charles River,
San Diego, CA) were distributed randomly and acclimated
for at least 1 week prior to any procedures or treatment. Mice
(𝑁 = 10/group) were immunized intranasally with NaVCP
VLPs (25 𝜇g) alone on days 0 and 21 and compared to mock-
vaccinated (PBS alone) controls. Mice were not anesthetized
for nasal immunization. Intranasal immunization was per-
formed by using a 20𝜇L pipet to instill half of the vaccine
into each nare (∼5–10𝜇L/nare). Serum was collected during
the entire timecourse (days 0, 12, 21, 42, and 56) as previously
described [38]. After the animals were humanely euthanized,
nasal lavages were collected and processed as previously
described [38]. All samples were stored at −80∘C for future
analysis of antibody titers. Serum and nasal samples were
evaluated by ELISA as previously described [38] and outlined
above. Sample dilutions included the following ranges: serum
(1 : 100–1 : 10,000,000) and nasal samples (1 : 2–1 : 5000). An
absorbance value of 0.1 or higher was considered to be
positive and the geometric mean titer (GMT) was calculated
as the reciprocal of the highest dilution tested that provided
a positive absorbance value.
2.11. Statistical Analyses. Statistical analysis was performed
using Prism software (GraphPad; San Diego, CA). Geometric
mean titer (GMT) values were evaluated statistically at
each time point using the Mann-Whitney nonparametric
test. Statistical comparisons between the NaVLP vaccination
group and the PBS delivery (mock-vaccinated) group were
completed and displayed in Figure 4. A P value < 0.05 was
considered statistically significant.
3. Results
3.1. Transient Expression of NaVCP inNicotiana benthamiana.
A TMV-based ICON expression vector was utilized for
efficient expression of NaVCP.This TMV vector is based on a
deconstructed viral system for expression of gene of interest
[21, 24, 25, 34]. The NaVCP coding sequence was cloned into
the 3󸀠 module, and when delivered in combination with 5󸀠
module and integrase module, the system drives the expres-
sion of NaVCP in the cytoplasm. Three days postinfiltration
(DPI), total RNA was extracted from the N. benthamiana
leaf and RNA blot was performed with 3󸀠UTR specific
probe. Both NaVCP transcripts (genomic RNA, ∼8 kb and
subgenomic RNA, ∼2 kb) at expected sizes (Figure 1(a)) were
detected. The same RNA blot was restriped and reprobed
with NaVCP specific probe (data not shown) to confirm the
results. Although high expression of foreign proteins has
been obtained using the ICON system, NaVCP expression in
plants promoted the rapid onset of tissue necrosis at∼5-6DPI
(Figure 1(d)). In spite of the need to harvest at 4DPI (much
earlier than NVCP, [21]), approximately 0.28mg of NaVCP
per g fresh leaf weight was obtained, as quantified by NaVCP
ELISA (Table 1). Plant-derived NaVCP was also detected in
the Coomassie stained SDS-PAGE gels loaded with crude
protein extracts from N. benthamiana (Figure 1(b), lane 4)
and was confirmed by Western blot probed with polyclonal
rabbit anti-NaVCP antibody (Figure 1(c), lane 3). The plant-
derivedNaVCPcomigratedwith insect cell-derivedNaVCPat
the expected size of 58 kDa (Figure 1(b) lane 2 and Figure 1(c)
lane 1) and was absent in leaves infiltrated with an empty
vector (Figure 1(b) lane 3 and Figure 1(c) lane 2). The insect-
derived VLP sample also had a smaller ∼50 kDa protein,
which is consistent with insect-based expression of various
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Figure 1: Initial characterization of transient expression of NaVCP. (a) Northern blots of RNA from leaves infiltrated with pICHsNaV (lane
2) showing genomic RNA (gRNA) and subgenomic RNA (sgRNA) of NaVCP after 3DPI. Lane 1 is noninfiltrated leaf as negative control. Two
𝜇g of total RNA was loaded and probed with probe specific to TMV 3󸀠UTR. Ribosomal RNA loading is shown at the bottom. (b) Coomassie
stained SDS-PAGE of NaVCP showing presence of NaVCP at expected size ∼58 kDa. Lane 1: protein molecular mass markers; lane 2: insect-
derived NaVCP (1𝜇g); lane 3: crude protein extract (15𝜇g) from leaves infected with empty vector; lane 4: crude protein extract (15𝜇g) from
leaf samples infiltrated with pICHsNaV and harvested at 4DPI. The 64 kDa and 48 kDa molecular mass markers are indicated by arrows at
left. (c) Western blot of SDS-Page of sNaVCP showing presence of NaVCP at expected size ∼58 kDa. Lane 1: insect-derived NaVCP (25 ng);
lane 2: crude protein extract (10𝜇g) from leaves infected with empty vector. Lane 3: crude protein extract (10𝜇g) from leaf samples infiltrated
with pICHsNaV and harvested at 4DPI. (d) Hypersensitive response on pICHsNaV infiltrated region. Part of the leaf that was infiltrated with
pICHsNaV displayed cell death 5DPI whereas such symptoms are absent in infiltrated areas of GFP, NVCP, and empty vector (Neg). Inset
shows GFP fluorescence at 10DPI.
norovirus capsids and attributed to either an alternative
translation initiation site or to proteolytic cleavage [39].Thus,
the plant-based system provided an advantage in that only
full-length NaVCP was observed.
3.2. Plant-Derived NaVCP Assembles VLPs. Sucrose gradient
sedimentation was performed to confirm VLP assembly of
plant-derived NaVCP. Crude protein extracts from N. ben-
thamiana and insect derived NaVCP were separately layered
on 10–60% sucrose gradients. The gradient fractions (1–15)
from top to bottom were analyzed by NaVCP ELISA and also
confirmed by Western blot on selected fractions (data not
shown). The profiles revealed two peak fractions (∼2-3 and
Table 1: NaVCP accumulation in N. benthamiana leaf at different
times after infiltration with Agrobacteria.
DPI 𝜇g/g fresh wt. % NaVCP/TSP
3 198 ± 11 1.30 ± 0.10
4 285 ± 3 1.89 ± 0.25
5 Necrosis observed
DPI: days postinfiltration.
∼10–12) for plant-derived NaVCP (Figure 2(a)). Interestingly,
plant-derived NaVCP showed a faster sedimenting peak at
fraction 11 whereas insect-derived NaVCP exhibited a peak
at fraction 6. To examine VLP, pooled faster sedimenting
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Figure 2: NaVLP assembly and electron microscopy. (a) Sucrose
gradient sedimentation for evaluation of VLP assembly for plant-
and insect-derived NaVLP. Crude extracts from N. benthamiana
infiltrated with pICHsNaV or purified insect-derived NaVLP were
sedimented separately on 10–60% sucrose gradients and 15 fractions
were collected. Distribution of NaVCP across the gradient fractions
was determined by ELISA.The top of the gradient is at left. Fractions
5 to 14 were pooled for EM studies. (b) Visualization by electron
microscopy of NaVLP. Left: plant-derived NaVLP partially purified
by sucrose gradient, immunocaptured on grids, and negatively
stained; arrow indicates 33 nm VLP. Right: insect-derived NaVLP;
arrows indicate small ∼20 nm VLP. Bars = 100 nm.
fractions (5–14) from plant samples were immobilized using
rabbit anti-NaVCP antibody followed by negative staining
and visualized by electronmicroscopy. Both plant and insect-
derived samples showed particles that were approximately
33 nm in diameter (Figures 2(b)) and appeared similar to
Norwalk VLP [19, 21, 40]. Both samples but especially the
insect-derived sample also contained smaller VLP with a
diameter of ∼20 nm, consistent with the 23 nm Norwalk
VLP obtained from insect cells [19]. The slower sedimenting
fractions in the plant samples most likely represent VLP
assembly intermediates.
3.3. Partial Purification of NaVCP from N. benthamiana. In
order to conduct immunization studies, various methodolo-
gies for purifying plant-derived NaVLP were investigated.
In a previous study [19, 21, 40], pH 5.7 precipitation of
60
50
(kDa)
1 2 3
sNaV
L-Rb
S-Rb
Figure 3: Partial purification of NaVCP expressed in N. ben-
thamiana leaf. Coomassie stained gel showing partially purified
NaVCP afterDEAE chromatography. Lane 1: proteinmolecularmass
markers; lane 2: concentrated plant extract beforeDEAEchromatog-
raphy; lane 3: DEAE chromatography flow-through containing
NaVCP. sNaV: Narita virus capsid protein; L-Rb: large subunit of
Rubisco; S-Rb: small subunit of Rubisco.
Table 2: Extraction efficiency of NaVCP using different pH for
buffer.
pH 𝜇g/g fresh wt. % NaVCP/TSP
5.7 53 ± 18 0.7 ± 0.15
6.6 133 ± 22 1.4 ± 0.16
plant proteins, especially ribulose bisphosphate carboxylase
(Rubisco), was used in an attempt to partially purify NVCP.
However, utilizing a similar strategy resulted in substantial
loss of NaVCP as compared to NVCP. When the pH of the
extraction buffer was raised from pH 5.7 to pH 6.6, the
concentration of extracted NaVCP was much higher in the
soluble fraction (Table 2) and minimal loss (less than 10%)
was observed in the insoluble pellet (data not shown). The
supernatant was concentrated by filtering through a 300 kDa
cut-off membrane to remove some of the plant endogenous
proteins followed by 30 kDa cut-offmembrane to concentrate
the extracted NaVCP.
The final concentrated extract was further fractionated
using anion exchange chromatography to yield partially
purified NaVCP extract. The majority of the NaVCP was
contained in the flow-through fraction (Figure 3, lane 3),
while the two major endogenous plant proteins, large and
small subunit of Rubisco, which comprise ∼50% of the leaf
protein, were lacking in the flow-through fraction. Rubisco
subunits were finally eluted in the high salt buffer. The
flow-through fractions were pooled, concentrated further,
and used for immunization studies. The DEAE purified
NaVCP used for animal studies was ∼5% of total soluble
protein (TSP) as measured by ELISA.
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Figure 4: Intranasal immunization with NaVLP induced significant serum and mucosal VLP-specific antibody production in mice. Female
BALB/c mice (𝑛 = 10 per group) received intranasal delivery of plant-derived NaVCP [25𝜇g] on day 0 and day 21. Time course analysis of
VLP-specific serum IgG and IgG isotypes ((a)–(c)) and nasal IgA (d) responses in mice following intranasal delivery of plant-derived NaVLP.
Serum IgG, IgG isotypes, and nasal IgA were measured by ELISA. The 𝑦-axis shows the geometric mean titers (GMTs) and the error bars
show the standard error of the mean. A P value of <0.05 was considered significant. ∗ < 0.01 and ∗∗ < 0.001.
3.4. Intranasal Vaccination with NaVCP Induces Serum and
Mucosal VLP-Specific Antibody Responses. To evaluate the
immunogenicity of the plant-derived NaVCP, female mice
were intranasally vaccinated with NaVLP (25 𝜇g) or mock-
vaccinated (PBS treated) on days 0 and 21. Serum was
collected on days 0, 12, 21, 42, and 56 after vaccination
and evaluated for VLP-specific antibody production. Nasal
washes were collected at the end of the study (day 56) follow-
ing euthanasia. By day 21, a significant amount of Narita VLP-
specific antibodies was produced in the antigen-containing
group relative to the mock PBS controls (Figure 4(a)). The
amount of VLP-specific IgG and IgG isotype antibody in the
serum continued to rise over the period of the study through
day 56 (Figures 4(a)–4(c)). Consistent with studies using NV
VLP alone (without adjuvant), IgG1 levels were much higher
relative to the IgG2a isotype indicating a predominately
Th2 response [38, 41]. A significant amount of VLP-specific
nasal IgA production was observed in the NaVCP vaccinated
mice relative to the mock-vaccinated controls (Figure 4(d)),
indicating a robust local response. Thus, NaVLP delivered
intranasally resulted in significant levels of VLP-specific
antibody at serum and mucosal sites (Figure 4).
4. Discussion
VLPs have been used as vaccines as a safer alternative to
attenuated live or inactivated killed viruses. VLP-based vac-
cines have been successful in the clinic; for example, there are
two commercially available HPV VLP-based vaccines [42].
Recombinant Norwalk (rNV) VLPs are being investigated
as vaccine candidates in the clinic as the VLPs are mor-
phologically and antigenically similar to Norwalk virus as
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demonstrated by electron microscopy and ELISA [17, 20, 43,
44]. Initial studies using insect-derived rNV VLP expressed
via baculovirus expression system were immunogenic in
mice [17, 20, 45]. Using adjuvants and formulations can
significantly enhance the mucosal immunogenicity of plant-
based VLP vaccines as recently shown [38, 41, 46].
For the last decade, plant-based vaccines have gained
steady acceptance in the scientific community. Plant-based
expression is a cost-effective and convenient system for
antigens to be used in mucosal delivery. Plants represent
relatively safe platforms to express vaccines since they are
free of mammalian pathogens that affect other production
systems such as transgenic animals and cell lines [29, 30].
Norwalk VLPs have been previously shown to accumulate in
transgenic potato [18], tobacco [18, 21], and tomato [40, 47].
Very high expression (0.8mg/g leaf) ofNVVLPswas attained
in transient assay using viral vectors TMV-based expression
system in N. benthamiana [21]. In this study, feasibility of
high-level expression of norovirus Narita 104 was explored
for use as subunit vaccine. Narita 104 virus is a GII.4 strain
of norovirus similar to those responsible for recent outbreaks
[48].
NaVCP was expressed using a replicating plant virus
based strategy to yield high levels of protein expression [24].
In this strategy, NaVCP was inserted among viral replicating
elements, amplified episomally, and subsequently translated
in the cytosol of plant cell. Expression in N. benthamiana
required partial purification of the protein prior to using
it in immunization studies. A high level of expression of
foreign protein (0.5–5 mg recombinant protein per g of leaf
biomass) has been obtained with the TMV based systemwith
no signs of necrosis on the infiltrated plants [49]. NVCP,
which is similar to NaVCP, was expressed at 0.8mg/g leaf
in N. benthamiana at 12DPI and necrosis was not observed
even after 22DPI [21]. However, expression of NaVCP was
limited due to rapid emergence of a hypersensitive response-
like symptom followed by cell death by 5DPI. In spite of this
shorter infection time, expression of NaVCP was reasonably
high, attaining 0.3mg/g leaf. A similar response was observed
when expression of NaVCP was driven by a geminiviral
vector system [39] in N. benthamiana (Mathew, LG., and
Mason HS., unpublished data). In spite of the cell death
response, expression observed with the TMV system was
approximately 55-fold higher than the transient expression
in N. benthamiana leaf using a nonreplicating vector system
(Mathew, LG., and Mason, HS. unpublished data).
The rapid induction of a leaf cell death response by
NaVCP is interesting, since the related NVCP showed no
such response [21]. The capsid proteins of Norwalk and
Narita 104 viruses are substantially divergent, with amino
acid sequences 45% identical and 60% similar over the
entire length. The capsid proteins have similar protein
structures comprising shell (S) and protruding (P) domains
[50]. The S domains are more highly conserved, and the
P1 subdomains are moderately well conserved. However,
the most surface-exposed P2 subdomains are the most
variable, and NaVCP has a 10-aa insertion “QTGQNTK-
FTP.” We performed P2 subdomain swapping experiments;
however, when the chimeric capsid proteins were expressed
in N. benthamiana, the results were inconclusive and failed
to show convincing evidence of the direct involvement of
P2 in the induction of cell death by NaVCP (Mathew and
Mason, unpublished data). Nonetheless, it seems likely that
the sequence divergence is related to the great difference in
induction of the cell death response and could bemediated by
host cell defense responses that recognize a particular pattern
in NaVCP.
The evidence that plant-derived NaVCP assembles into
NaVLP strengthens the finding that plant-derivedNaVCP can
be used as a vaccine candidate. The observation that plant-
and insect-derived NaVLP showed different sucrose gradient
sedimentation profiles may be explained in several ways.
The electron micrograph of insect-derived NaVLP showed
that most particles appeared to be either partially assembled,
characterized by a deeper electron dense stain, or small 20 nm
VLP (Figure 2(b) right). The plant-derived NaVLP appeared
to be mostly fully assembled with rare occurrence of 20 nm
VLPs (Figure 2(b) left). The partially assembled and smaller
20 nm VLPs were likely slower sedimenting than the plant-
derived VLPs. Another possibility is that plant-derived VLP
formed aggregates, perhaps by interaction with endogenous
cellular material and, therefore, sedimented faster. Further
studies need to be conducted in order to understand the
difference in the sedimentation pattern from insect-derived
and plant-derived NaVLP.
In spite of the relatively shorter infection period due to
induction of hypersensitive response, useful yields of NaVCP
were obtained. The crude extract had a significantly large
amount of endogenous plant protein, including Rubisco,
which constitutes ∼50% of the total leaf protein [51]. A
strategy using pH 5.7 extraction buffer [21], resulted in
substantial loss (almost half) of the NaVCP protein in
the supernatant (Table 2). The size exclusion concentration
aided in the removal of plant endogenous protein and some
partially assembled particles. However, the final concentrate
did show a substantial amount of Rubisco, both large and
small subunits (Figure 3, lane 2). Most of the Rubisco was
removed in the final anion exchange chromatography by
maintaining the buffer at acidic pH (Figure 3, lane 3).
The partially purified NaVLPs were intranasally delivered
to mice to determine the level of immunogenicity both
systemically and at the local mucosal immunization site.
In the absence of adjuvant, nasal immunization resulted
in the significant induction of VLP-specific antibodies in
serum and nasal secretions. Therefore, this GII.4-specific
vaccine candidate was immunogenic, thus validating the use
of plant-derived NaV as a norovirus vaccine or component
for a multivalent formulation. Further, we have seen no
difference in antibody responses produced by insect cell-
derived and plant-derived norovirus VLP prepared similarly
and delivered at comparable doses (data not shown). Another
indication of the biosimilarity of plant and insect cell-derived
VLP is that mice immunized with tomato-derived Norwalk
VLP were strongly boosted using insect cell-derived VLP
[39].
Although the VLP sample was relatively impure
(Figure 3), the robust immune responses in vaccinated mice
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suggest that contaminating leaf proteins did not impair
the immunogenicity of VLP. Additional studies will need
to be conducted to optimize the purification, formulation,
delivery route, and immunogenicity of this VLP-based
vaccine candidate.There is no small animal model or in vitro
propagation assay for human norovirus; therefore, it would
be difficult to determine if the antibody levels generated
in this study would correlate to protection from challenge.
For the purpose of this study we aimed to determine the
immunogenicity of the GII-specific norovirus VLP vaccine
candidate. Future studies will optimize this formulation
and test for blockade of VLP binding to histoblood group
antigens specific for this genogroup of norovirus.
In conclusion, our plant-based expression technology
provided a convenient platform for expedient and cost-
effective production of immunogenic recombinant NaVLPs
for vaccine studies. Future preclinical studies that include
plant-derived GII-4-specific VLP within a multivalent vac-
cine will be required to determine if this approach can
be exploited for generating a protective norovirus vaccine
formulation.
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